Mazanti advises Sunstone Life Science Ventures on their investment in biotech company STipe Therapeutics

STipe Therapeutics, founded in 2018 and led by CEO Dr. Claus Elsborg Olesen, has raised €20m in series A financing. STipe is an Aarhus-based biotech company focusing on harnessing the innate immune system to battle cancer and target a range of hematological and solid tumors. The company is developing first in class drugs targeting intracellular protein-protein interactions of the STING Pathway, and its innovative technology has demonstrated that it can significantly increase the sensitivity of the innate immune system to rapidly detect even a small amount of tumor-DNA.

Sunstone Life Science Ventures, an independent European venture capital investment firm founded in 2007, is investing as part of an international syndicate including Novo Holdings, Arix Bioscience plc and Wellington Partners Life Science V Fund.

Sunstone General Partner, Sten Verland, who will join STipe Therapeutics’ Board of Directors, commented:
“We are excited about the potential of STipe’s novel technology harnessing the effect of the STING pathway. We look forward to leveraging our experience in this exciting field and working with founders and the other investors to bring STipe’s technology into clinical development”.

Read more about the investment here and here.